

South East London Area Prescribing Committee

Withdrawal of formulary recommendation number 016 (issued November 2014):

Golimumab (Simponi®) injection for the treatment of ulcerative colitis

This formulary recommendation has been withdrawn from local use as it has been superseded by NICE Technology Appraisal Guidance (TAG) number 329: *Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy*.

The NICE TAG (published February 2015) can be accessed <u>here</u>.

The local SEL IBD pathways can be accessed <u>here</u>.

Please contact <u>contactus@selondonics.nhs.uk</u> for further information.

20th April 2015